Want to join the conversation?
Andrew Finkelstein of Susquehanna Financial Group asks about commercial execution priorities for 2H16. $AGN said the most important one is RESTASIS. $AGN increased its salesforce by 20% and also its investment in direct-to-consumer advertising. Viberzi and Kybella are the other priorities. The coverage of ophthalmology and optometry will be higher.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?